E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment |
Infecciones pulmonares por micobacterias no tuberculosas (MNT) causadas por el complejo Mucobacterium avium (CMA) que son resistentes al tratamiento |
|
E.1.1.1 | Medical condition in easily understood language |
Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment |
Infecciones pulmonares por micobacterias no tuberculosas (MNT) causadas por el complejo Mucobacterium avium (CMA) que son resistentes al tratamiento |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10058806 |
E.1.2 | Term | Mycobacterium avium complex infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of LAI (590 mg) administered once daily (QD), when added to a multi-drug regimen, for achieving culture conversion (3 consecutive negative sputum cultures) by Month 6 compared to a multi-drug regimen alone |
Evaluar la eficacia de la LAI (590 mg) administrada una vez al día (1 v/d) y añadida a una politerapia para lograr la conversión de los cultivos (3 cultivos de esputo negativos consecutivos) para el mes 6 en comparación con la politerapia sola |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of LAI (590 mg) administered QD when added to a multi-drug regimen 1. on the six-minute walk test (6MWT) at Month 6 compared to a multi-drug regimen alone 2. for time to culture conversion compared to a multi-drug regimen alone 3. for achieving sustainability (consecutive negative sputum cultures [with no more than 2 consecutive broth positive cultures] for 12 months on treatment) compared to a multi-drug regimen alone 4. on the durability of treatment success 3 months after the end of total treatment course (negative sputum culture after 3 months off-treatment) 5. on the 6MWT at End of Therapy (EOT) compared to a multi-drug regimen alone 6. To evaluate patient-reported symptoms of NTM and change from baseline (Day 1) in quality of life scores on the St. George?s Respiratory Questionnaire (SGRQ) at Month 6
For exploratory, safety and pharmacokinetic objectives please refer to protocol synopsis on page 5 and 6 |
Evaluar la eficacia de la LAI (590 mg) administrada 1 v/d y añadida a una politerapia 1.en la prueba de la marcha de seis minutos (PM6M) en el mes 6 en comparación con la politerapia sola 2.en el tiempo hasta la conversión de los cultivos en comparación con la politerapia sola 3.para lograr la sostenibilidad (cultivos de esputo negativos consecutivos [con no más de 2 cultivos positivos consecutivos en caldo] para 12 meses con tratamiento) en comparación con politerapia sola 4.en la durabilidad del éxito del tratamiento 3 meses después del fin del ciclo de tratamiento total (cultivo en esputo negativo después de 3 meses sin tratamiento) 5.en la PM6M en el fin del tratamiento (FdT) en comparación con la politerapia sola 6.Evaluar los síntomas de MNT referidos por el paciente y el cambio respecto al inicio (día 1) en las puntuaciones en la calidad de vida en el Cuestionario respiratorio de St. George (SGRQ) en el mes 6 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. be male or female, 18 years or older 2. be continually positive for MAC on sputum culture while adhering to a multi-drug treatment regimen for a minimum duration of 6 months which is either ongoing or was stopped no more than 12 months before screening 3. be diagnosed with MAC NTM lung infection with evidence of nodular bronchiectasis and/or fibrocavitary disease by chest CT 4. have a MAC lung infection documented by at least 2 positive cultures (MAC or mixed infection with MAC as the dominant species) with at least one obtained within 6 months prior to and/or including screening.. Cultures may be obtained from sputum or bronchoscopy. 5. have a MAC-positive sputum at screening 6. be willing to adhere to multi-drug treatment regimen during the course of the study 7. be able to produce at least 3 mL of sputum or be willing to undergo an induction that produces at least 3 mL of sputum for mycobacteriology 8. female of childbearing potential agrees to practice an acceptable method of birth control (e.g., abstinence, hormonal or barrier methods, partner sterilization, or IUD) 9. provide written informed consent before performing any study related procedure 10. be willing to have serum specimens stored 11. be able to comply with study medication use, study visits, and study procedures as determined by the investigator |
1.Ser varón o mujer mayor de 18 años 2.Obtener resultados siempre positivos en los cultivos de CMA en esputo mientras recibe una politerapia de una duración mínima de 6 meses que está en curso o finalizó no más de 12 meses antes de la selección 3.Estar diagnosticado de infección pulmonar por MNT CMA con signos de bronquiectasia nodular o enfermedad fibrocavitaria según la TAC de tórax 4.Tener una infección pulmonar por CMA demostrada por al menos 2 cultivos positivos (CMA o infección mixta con CMA como especie dominante), de los que al menos uno se obtuvo en los 6 meses previos a la selección o durante la misma. Los cultivos pueden obtenerse del esputo o la broncoscopia. 5.Tener un cultivo de esputo positivo para CMA en la selección 6.Estar dispuesto a cumplir una politerapia durante el transcurso del estudio 7.Poder producir al menos 3 ml de esputo o estar dispuesto a someterse a una inducción que produzca al menos 3 ml de esputo para micobacteriología 8.Si es mujer en edad fértil, acceder a utilizar un método anticonceptivo aceptable (p. ej., abstinencia, métodos hormonales o de barrera, esterilización de la pareja o DIU) 9.Dar su consentimiento informado por escrito antes de la realización de los procedimientos del estudio 10.Estar dispuesto al almacenamiento de muestras de suero 11.Ser capaz de cumplir el uso del fármaco en estudio, las visitas y los procedimientos del estudio que determine el investigador |
|
E.4 | Principal exclusion criteria |
1. patients with cystic fibrosis 2. patients whose MAC NTM infection is resistant to amikacin (as identified by mutation on RNA sequencing) 3. patients who are not able to perform the 6MWT 4. positive pregnancy test or lactation at screening. All women of child bearing potential will be tested. Women not of childbearing potential are defined as postmenopausal (i.e., amenorrheic for at least 1 year), or surgically or naturally sterile. 5. active pulmonary malignancy (primary or metastatic) or any malignancy requiring chemotherapy or radiation therapy within 1 year before screening or anticipated during the study period 6. active allergic bronchopulmonary mycosis or any other condition requiring chronic systemic corticosteroids at a dose greater than the equivalent of 10 mg/day of prednisone within 3 months before screening 7. active pulmonary tuberculosis requiring treatment at screening 8. history of lung transplantation 9. initiation of chronic therapy (e.g., high-dose ibuprofen, inhaled anti-inflammatory agents including steroids, low dose maintenance steroids, recombinant human deoxyribonuclease [rhDNase]) within 28 days before Day 1. 10. administration of any investigational drug within 8 weeks before screening 11. prior exposure to LAI (including clinical study). 12. known hypersensitivity to aminoglycosides 13. use of inhaled or systemic aminoglycosides (e.g., tobramycin, amikacin, gentamicin, or streptomycin) within 28 days before Day 1 14. acquired and primary immunodeficiency syndromes 15. significant (as determined by the investigator) hearing loss, vestibular dysfunction, or neuromuscular weakness where the potential risk of aminoglycoside toxicity outweighs the potential benefit 16. aspartate aminotransferase or alanine aminotransferase ? 3 times the upper limit of normal (ULN) or total bilirubin ? 2 times the upper limit of normal (ULN) at screening 17. absolute neutrophil count ?500/?L at screening 18. serum creatinine >2 times ULN at screening 19. current alcohol, medication or illicit drug abuse 20. any condition that, in the opinion of the Investigator, interferes with ability to safely complete the study or adhere to study requirements 21. persons who have been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities |
1.Pacientes con fibrosis quística 2.Pacientes con infección por MNT CMA resistente a la amicacina (identificados como mutación en la secuenciación del ARN) 3.Pacientes que no pueden realizar la PM6M 4.Prueba de embarazo positiva o lactancia en la selección. Todas las mujeres en edad fértil se someterán a la prueba. Las mujeres que no están en edad fértil son las posmenopáusicas (esto es, amenorreicas durante al menos 1 año) o estériles quirúrgicamente o de manera natural 5.Cáncer pulmonar activo (primario o metastásico) o cáncer que requiera quimioterapia o radioterapia en el año previo a la selección o prevista durante la fase del estudio 6.Micosis broncopulmonar alérgica activa o cualquier otra afección que requiera corticosteroides sistémicos crónicos a una dosis superior al equivalente de 10 mg/día de prednisona en los 3 meses previos a la selección 7.Tuberculosis pulmonar activa que requiera tratamiento en la selección 8.Trasplante pulmonar previo 9.Inicio de tratamiento crónico (p. ej., ibuprofeno en dosis altas, antiinflamatorios inhalados como esteroides, esteroides de mantenimiento en dosis bajas,deoxyribonucleasa hmana recombinande ( rhDNasa)) en los 28 días previos al día 1 10.Administración de un fármaco en investigación en las 8 semanas previas a la selección 11.Exposición previa a la LAI (incluidos los estudios clínicos) 12.Hipersensibilidad conocida a los aminoglucósidos 13.Uso de aminoglucósidos inhalados o sistémicos (p. ej., tobramicina, amicacina, gentamicina o estreptomicina) en los 28 días previos al día 1 14.Síndromes de inmunodeficiencia adquirida o primaria 15.Pérdida auditiva significativa (según lo determine el investigador), disfunción vestibular o debilidad neuromuscular en que el posible riesgo de toxicidad de los aminoglucósidos supere el posible beneficio 16.Aspartato aminotransferasa o alanina aminotransferasa ? 3 veces el límite superior de la normalidad (LSN) o bilirrubina total ? 2 veces el LSN en la selección 17.Cifra absoluta de neutrófilos ? 500/?l en la selección 18.Creatinina sérica > 2 veces el LSN en la selección 19.Alcoholismo, abuso de medicamentos o drogodependencia en la actualidad 20.Cualquier afección que, en opinión del investigador, interfiera en la capacidad de realizar el estudio con seguridad o cumplir con sus requisitos 21.Personas internadas en una institución en virtud de una orden emitida por las autoridades judiciales o administrativas |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the proportion of subjectsachieving culture conversion (3 consecutive negative sputum cultures collected monthly without relapse or recurrence) by Month 6 in the LAI arm compared to multi-drug regimen alone. |
El criterio de valoración principal es la proporción de pacientes que logran la conversión de los cultivos (3 cultivos de esputo negativos consecutivos recogidos mensualmente sin recaída ni recidiva) para el mes 6 en el grupo de LAI más politerapia en comparación con la politerapia sola |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Evaluation of primary endpoint will be done at Month 8 |
La valoración del principal criterio de valoración será realizada al mes 8 |
|
E.5.2 | Secondary end point(s) |
SECONDARY EFFICACY ENDPOINTS 1. Change in 6MWT distance at Month 6 in the LAI arm compared to a multi-drug regimen alone 2. Time to culture conversion in the LAI arm compared to a multi-drug regimen alone at Month 6 3. Proportion of subjects achieving culture conversion with sustainability at the EOT in the LAI arm compared to a multi-drug regimen alone 4. Proportion of subjects achieving culture conversion with durability at the EOS (3 months off treatment) in the LAI arm compared to a multi-drug regimen alone in all evaluable subjects 5. Change in 6MWT distance at EOT in the LAI arm compared to a multi-drug regimen alone 6. The mean change from baseline (Day 1) at Month 6 in the SGRQ.
EXPLORATORY ENDPOINTS 1. Change in 6MWT distance at Month 8 in the LAI arm compared to a multi-drug regimen alone 2. Change in 6MWT distance at EOS in the LAI arm compared to a multi-drug regimen alone 3. The mean change from baseline (Day 1) at Month 6 in the SGRQ ? Part 2 (Activities of Daily Livings) 4. The mean change from baseline (Day 1) at EOT in the EQ-5D 5. Proportion of subjects who develop a new strain of MAC in the LAI arm compared to multi-drug regimen alone 6. Radiological changes in CT Scan at EOT in the LAI arm compared to multi-drug regimen alone, where appropriate 7. Mortality at EOS. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From baseline till end of study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
Canada |
France |
Germany |
Israel |
Italy |
Japan |
Netherlands |
New Zealand |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 7 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 7 |